Signature program

A platform of basket trials

Eric D. Slosberg, Barinder P. Kang, Julio Peguero, Matthew Taylor, Todd M. Bauer, Donald A. Berry, Fadi Braiteh, Alexander Spira, Funda Meric-Bernstam, Steven Stein, Sarina A. Piha-Paul, August Salvado

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    Investigating targeted therapies can be challenging due to diverse tumor mutations and slow patient accrual for clinical studies. The Signature Program is a series of 8 phase 2, agent-specific basket protocols using a rapid study start-up approach involving no predetermined study sites. Each protocol evaluated 1 agent (buparlisib, dovitinib, binimetinib, encorafenib, sonidegib, BGJ398, ceritinib, or ribociclib) in patients with solid or hematologic malignancies and an actionable mutation. The primary endpoint of each study was the clinical benefit rate (ie, complete or partial response, or stable disease) at 16 weeks. A total of 192 individual sites were opened in the United States, with a median start-up time of 3.6 weeks. The most common tumor types among the 595 treated patients were colorectal (9.2%), non-small cell lung adenocarcinoma (9.1%), and ovarian (8.4%). Frequent genetic alterations were in PIK3CA, RAS, p16, and PTEN. Overall, 30 partial or complete responses were observed with 6 compounds in 16 tumor types. The Signature Program presents a unique and successful approach for rapid signal finding across multiple tumors and allowed various agents to be evaluated in patients with rare alterations. Incorporating these program features in conventional studies could lead to improved trial efficiencies and patient outcomes.

    Original languageEnglish (US)
    Pages (from-to)21383-21395
    Number of pages13
    JournalOncotarget
    Volume9
    Issue number30
    DOIs
    StatePublished - Apr 20 2018

    Fingerprint

    Neoplasms
    Mutation
    Hematologic Neoplasms
    Clinical Studies
    Therapeutics
    Adenocarcinoma of lung
    NVP-BKM120
    ribociclib
    LDE225
    3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
    ceritinib
    MEK162
    4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
    encorafenib

    Keywords

    • Basket trial
    • Clinical trial design
    • Mutations
    • Signature
    • Tissue agnostic

    ASJC Scopus subject areas

    • Oncology

    Cite this

    Slosberg, E. D., Kang, B. P., Peguero, J., Taylor, M., Bauer, T. M., Berry, D. A., ... Salvado, A. (2018). Signature program: A platform of basket trials. Oncotarget, 9(30), 21383-21395. https://doi.org/10.18632/oncotarget.25109

    Signature program : A platform of basket trials. / Slosberg, Eric D.; Kang, Barinder P.; Peguero, Julio; Taylor, Matthew; Bauer, Todd M.; Berry, Donald A.; Braiteh, Fadi; Spira, Alexander; Meric-Bernstam, Funda; Stein, Steven; Piha-Paul, Sarina A.; Salvado, August.

    In: Oncotarget, Vol. 9, No. 30, 20.04.2018, p. 21383-21395.

    Research output: Contribution to journalArticle

    Slosberg, ED, Kang, BP, Peguero, J, Taylor, M, Bauer, TM, Berry, DA, Braiteh, F, Spira, A, Meric-Bernstam, F, Stein, S, Piha-Paul, SA & Salvado, A 2018, 'Signature program: A platform of basket trials', Oncotarget, vol. 9, no. 30, pp. 21383-21395. https://doi.org/10.18632/oncotarget.25109
    Slosberg ED, Kang BP, Peguero J, Taylor M, Bauer TM, Berry DA et al. Signature program: A platform of basket trials. Oncotarget. 2018 Apr 20;9(30):21383-21395. https://doi.org/10.18632/oncotarget.25109
    Slosberg, Eric D. ; Kang, Barinder P. ; Peguero, Julio ; Taylor, Matthew ; Bauer, Todd M. ; Berry, Donald A. ; Braiteh, Fadi ; Spira, Alexander ; Meric-Bernstam, Funda ; Stein, Steven ; Piha-Paul, Sarina A. ; Salvado, August. / Signature program : A platform of basket trials. In: Oncotarget. 2018 ; Vol. 9, No. 30. pp. 21383-21395.
    @article{a6159777616e453f8b6fa2f5fc866e37,
    title = "Signature program: A platform of basket trials",
    abstract = "Investigating targeted therapies can be challenging due to diverse tumor mutations and slow patient accrual for clinical studies. The Signature Program is a series of 8 phase 2, agent-specific basket protocols using a rapid study start-up approach involving no predetermined study sites. Each protocol evaluated 1 agent (buparlisib, dovitinib, binimetinib, encorafenib, sonidegib, BGJ398, ceritinib, or ribociclib) in patients with solid or hematologic malignancies and an actionable mutation. The primary endpoint of each study was the clinical benefit rate (ie, complete or partial response, or stable disease) at 16 weeks. A total of 192 individual sites were opened in the United States, with a median start-up time of 3.6 weeks. The most common tumor types among the 595 treated patients were colorectal (9.2{\%}), non-small cell lung adenocarcinoma (9.1{\%}), and ovarian (8.4{\%}). Frequent genetic alterations were in PIK3CA, RAS, p16, and PTEN. Overall, 30 partial or complete responses were observed with 6 compounds in 16 tumor types. The Signature Program presents a unique and successful approach for rapid signal finding across multiple tumors and allowed various agents to be evaluated in patients with rare alterations. Incorporating these program features in conventional studies could lead to improved trial efficiencies and patient outcomes.",
    keywords = "Basket trial, Clinical trial design, Mutations, Signature, Tissue agnostic",
    author = "Slosberg, {Eric D.} and Kang, {Barinder P.} and Julio Peguero and Matthew Taylor and Bauer, {Todd M.} and Berry, {Donald A.} and Fadi Braiteh and Alexander Spira and Funda Meric-Bernstam and Steven Stein and Piha-Paul, {Sarina A.} and August Salvado",
    year = "2018",
    month = "4",
    day = "20",
    doi = "10.18632/oncotarget.25109",
    language = "English (US)",
    volume = "9",
    pages = "21383--21395",
    journal = "Oncotarget",
    issn = "1949-2553",
    publisher = "Impact Journals",
    number = "30",

    }

    TY - JOUR

    T1 - Signature program

    T2 - A platform of basket trials

    AU - Slosberg, Eric D.

    AU - Kang, Barinder P.

    AU - Peguero, Julio

    AU - Taylor, Matthew

    AU - Bauer, Todd M.

    AU - Berry, Donald A.

    AU - Braiteh, Fadi

    AU - Spira, Alexander

    AU - Meric-Bernstam, Funda

    AU - Stein, Steven

    AU - Piha-Paul, Sarina A.

    AU - Salvado, August

    PY - 2018/4/20

    Y1 - 2018/4/20

    N2 - Investigating targeted therapies can be challenging due to diverse tumor mutations and slow patient accrual for clinical studies. The Signature Program is a series of 8 phase 2, agent-specific basket protocols using a rapid study start-up approach involving no predetermined study sites. Each protocol evaluated 1 agent (buparlisib, dovitinib, binimetinib, encorafenib, sonidegib, BGJ398, ceritinib, or ribociclib) in patients with solid or hematologic malignancies and an actionable mutation. The primary endpoint of each study was the clinical benefit rate (ie, complete or partial response, or stable disease) at 16 weeks. A total of 192 individual sites were opened in the United States, with a median start-up time of 3.6 weeks. The most common tumor types among the 595 treated patients were colorectal (9.2%), non-small cell lung adenocarcinoma (9.1%), and ovarian (8.4%). Frequent genetic alterations were in PIK3CA, RAS, p16, and PTEN. Overall, 30 partial or complete responses were observed with 6 compounds in 16 tumor types. The Signature Program presents a unique and successful approach for rapid signal finding across multiple tumors and allowed various agents to be evaluated in patients with rare alterations. Incorporating these program features in conventional studies could lead to improved trial efficiencies and patient outcomes.

    AB - Investigating targeted therapies can be challenging due to diverse tumor mutations and slow patient accrual for clinical studies. The Signature Program is a series of 8 phase 2, agent-specific basket protocols using a rapid study start-up approach involving no predetermined study sites. Each protocol evaluated 1 agent (buparlisib, dovitinib, binimetinib, encorafenib, sonidegib, BGJ398, ceritinib, or ribociclib) in patients with solid or hematologic malignancies and an actionable mutation. The primary endpoint of each study was the clinical benefit rate (ie, complete or partial response, or stable disease) at 16 weeks. A total of 192 individual sites were opened in the United States, with a median start-up time of 3.6 weeks. The most common tumor types among the 595 treated patients were colorectal (9.2%), non-small cell lung adenocarcinoma (9.1%), and ovarian (8.4%). Frequent genetic alterations were in PIK3CA, RAS, p16, and PTEN. Overall, 30 partial or complete responses were observed with 6 compounds in 16 tumor types. The Signature Program presents a unique and successful approach for rapid signal finding across multiple tumors and allowed various agents to be evaluated in patients with rare alterations. Incorporating these program features in conventional studies could lead to improved trial efficiencies and patient outcomes.

    KW - Basket trial

    KW - Clinical trial design

    KW - Mutations

    KW - Signature

    KW - Tissue agnostic

    UR - http://www.scopus.com/inward/record.url?scp=85045838150&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85045838150&partnerID=8YFLogxK

    U2 - 10.18632/oncotarget.25109

    DO - 10.18632/oncotarget.25109

    M3 - Article

    VL - 9

    SP - 21383

    EP - 21395

    JO - Oncotarget

    JF - Oncotarget

    SN - 1949-2553

    IS - 30

    ER -